ARMO BioSciences Raises $67 Million in a Series C-1 Financing

Financing from New and Existing Investors Follows Encouraging Clinical Data Announced for Lead Product Candidate, AM0010, in Several Cancer Indications REDWOOD CITY, Calif., Aug. 29, 2017 -- (Healthcare Sales & Marketing Network) -- ARMO BioSciences, I... Biopharmaceuticals, Oncology, Venture Capital, Personnel ARMO BioSciences, pegilodecakin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news